Arcutis Biotherapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Todd Franklin Watanabe
- Full Time Employees
- 354
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3027 Townsgate Road Westlake Village CA United States of America 91361
- IPO Date
- Jan 31, 2020
- CIK
- 0001787306
- Website
- arcutis.com
- Similar Companies
- Business
- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) develops and commercializes topical therapies for immune-mediated inflammatory skin diseases, including plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp and body psoriasis, hidradenitis suppurativa, and vitiligo; its lead product, ZORYVE (roflumilast cream 0.3% and 0.15%), is FDA-approved for plaque psoriasis in adults and children aged 2 years and older, atopic dermatitis in adults and children aged 3 months and older (including low-dose formulations of 0.05% for ages 2-5 years and 3-24 months), and seborrheic dermatitis; ZORYVE foam (roflumilast 0.3%) is FDA-approved for seborrheic dermatitis and scalp and body psoriasis in adults; the company advances a pipeline featuring topical roflumilast across additional indications and ARQ-234, a topical biologic CD200R agonist in Phase 1 for atopic dermatitis. Founded in 2016 and headquartered in Westlake Village, California, Arcutis operates primarily in the United States, with partnerships extending to markets including China via Huadong Medicine, from which it received milestone payments of $3 million in Q1 2024 and $2 million in Q1 2025. Recent developments include robust ZORYVE sales growth to $99.2 million in Q3 2025, up significantly year-over-year, alongside FDA approval expansions for pediatric indications, preparation to initiate a Phase 1 trial for ARQ-234, and awards such as the 2025 Best of Beauty Breakthrough for ZORYVE cream and foam; the company continues strategic pipeline evaluation, including potential external innovations and a partnership with Kowa, while shifting market dynamics away from topical steroids.
Company News
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,728 Shares of Company Stock
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street Brokerages
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Masaru Matsuda Sells 3,674 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Here's Why You Should Add ARQT Stock to Your Portfolio Now
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Bamco Inc. NY Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT
5 Biotech Stocks Worth Adding to Your Portfolio Now
382,682 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Deutsche Bank AG
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates